Tiff Advisory Services LLC raised its stake in The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 13.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,979,141 shares of the company's stock after buying an additional 346,256 shares during the quarter. Oncology Institute makes up approximately 0.3% of Tiff Advisory Services LLC's investment portfolio, making the stock its 18th largest position. Tiff Advisory Services LLC owned about 3.94% of Oncology Institute worth $921,000 as of its most recent filing with the Securities & Exchange Commission.
Separately, HighTower Advisors LLC lifted its stake in shares of Oncology Institute by 190.8% in the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company's stock valued at $27,000 after purchasing an additional 53,382 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors.
Oncology Institute Trading Up 14.6 %
Shares of NASDAQ TOI traded up $0.09 during mid-day trading on Friday, reaching $0.72. 681,332 shares of the company's stock were exchanged, compared to its average volume of 837,171. The firm has a market capitalization of $54.10 million, a price-to-earnings ratio of -0.92 and a beta of 0.41. The Oncology Institute, Inc. has a 52-week low of $0.13 and a 52-week high of $1.94. The company's 50-day moving average is $0.68 and its 200-day moving average is $0.42. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49.
Oncology Institute Profile
(
Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
Further Reading
Before you consider Oncology Institute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.
While Oncology Institute currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
